Evidence map›Paper›PMID 37861886›Full record

ReviewJournal of applied genetics2024

The forerunners and successful partnerships behind the BioNTech mRNA vaccine.

Ilkin Aygün, Jan Barciszewski

Abstract readReview
In one paragraph

Review in Journal of applied genetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Neoantigen mRNA vaccines and AHuman vaccines & immunotherapeutics · 2025
    Review
  2. Article
  3. Application of Mammalian Nudix Enzymes to Capped RNA Analysis.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ilkin AygünInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Z. Noskowskiego, 12/14, 61-704, Poznan, Poland. iaygun@ibch.poznan.pl.ORCID http://orcid.org/0000-0002-1898-8673
Jan BarciszewskiInstitute of Bioorganic Chemistry, Polish Academy of Sciences, Z. Noskowskiego, 12/14, 61-704, Poznan, Poland.ORCID http://orcid.org/0000-0001-7766-5594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The discovery of nucleic acids stands as a paramount achievement in the history of scientific endeavors. By applying transformative advancements in the fields of chemistry and physics to biological systems, researchers unveiled the enigmatic nature of life. Notably, messenger RNA (mRNA) emerged as a crucial player in this profound revelation, serving as a transient intermediary for genetic information transfer between genes and proteins. Groundbreaking investigations carried out from 1944 to 1961 led to the initial identification of this pivotal molecule, captivating scientific interest for the past three decades. The field of mRNA research has witnessed a transformative shift owing to the development of cap analogs and nucleotide modifications. This revolutionary progress has fostered a new generation of potent therapeutics. Prior to the advent of the coronavirus pandemic, numerous scientists had already begun exploring the unique properties of mRNA. However, with the onset of the pandemic, mRNA catapulted into the limelight as a heroic agent, providing the foundation for highly effective vaccines that have played a crucial role in mitigating the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The successive generations of cap analogs have significantly enhanced the translation efficacy of mRNA, while the discovery of suitable purification, packaging, and delivery methods has paved the way for groundbreaking medical breakthroughs. Pioneers in the field such as Katalin Karikó, Drew Weissman, Edward Darzynkiewicz, Robert Rhodes, Ugur Sahin, and Ozlem Tureci have made significant contributions during the early stages of mRNA research, warranting acknowledgement for their visionary endeavors. The narrative of mRNA represents a remarkable journey marked by a succession of breakthroughs in a discipline that holds immense promise for the future of medicine. Thanks to the pioneering work of these exceptional scientists, we are well-positioned to unlock the full potential of this extraordinary molecule, ushering in a new era of medical advancements.

Indexed as

GastropodaVaccinesAnimalsmRNA VaccinesPandemicsRNA, MessengerSARS-CoV-2mRNA VaccinesRNA, MessengerVaccinesBioNTechCOVID-19mRNA technologyPandemicVaccine development

Identifiers

PMID37861886
PMCPMC10789661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.